Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries
Study centres, organisations, investigators and other research personnel (National Co-ordinators in each country are indicated by asterisk; EUROASPIRE V collaborators; Scientific Steering/ Executive Committee; Coordinating centre; Diabetes centre; Data management centre; Statistical analysis centre; Central laboratory
(2019) Atherosclerosis, volume 285, pp. 135 - 146
(Article)
Abstract
Background and aims: One of the objectives of the ESC-EORP EUROASPIRE V survey is to determine how well European guidelines on the management of dyslipidaemias are implemented in coronary patients. Methods: Standardized methods were used by trained technicians to collect information on 7824 patients from 130 centers in 27 countries,
... read more
from the medical records and at a visit at least 6 months after hospitalization for a coronary event. All lipid measurements were performed in one central laboratory. Patients were divided into three groups: on high-intensity LDL-C-lowering-drug therapy (LLT), on low or moderate-intensity LLT and on no LLT. Results: At the time of the visit, almost half of the patients were on a high-intensity LLT. Between hospital discharge and the visit, LLT had been reduced in intensity or interrupted in 20.8% of the patients and had been started or increased in intensity in 11.7%. In those who had interrupted LLT or had reduced the intensity, intolerance to LLT and the advice of their physician were reported as the reason why in 15.8 and 36.8% of the cases, respectively. LDL-C control was better in those on a high-intensity LLT compared to those on low or moderate intensity LLT. LDL-C control was better in men than women and in patients with self-reported diabetes. Conclusions: The results of the EUROASPIRE V survey show that most coronary patients have a less than optimal management of LDL-C. More professional strategies are needed, aiming at lifestyle changes and LLT adapted to the need of the individual patient.
show less
Download/Full Text
The full text of this publication is not available.
Keywords: Coronary heart disease, Dyslipidaemia, EUROASPIRE, LDL-Cholesterol, Lipid lowering therapy, Secondary prevention, Cardiology and Cardiovascular Medicine
ISSN: 0021-9150
Publisher: Elsevier
Note: Funding Information: The EUROASPIRE V survey was carried out under the auspices of the ESC –EORP. Since the start of EORP, the following companies have supported the programme: Amgen, Eli Lilly, Pfizer, Sanofi, Ferrer and Novo Nordisk. The sponsors of the EUROASPIRE surveys had no role in the design, data collection, data analysis, data interpretation, decision to publish, or writing the manuscript. The EUROASPIRE Study Group is grateful to the administrative staff, physicians, nurses, and other personnel in the hospitals in which the survey was carried out and to all patients who participated in the surveys. Funding Information: No competing interests for G. De Backer, D. De Bacquer, E. Mirrakhimov and D. Wood. P. Jankowski has received honoraria, research and conference grants from, KRKA, MSD, Pfizer, SanofiAventis, Servier, Zentiva. Ž Reiner has received honoraria for lectures from Sanofi Aventis and from Akcea. L.Tokozoglu has had financial interests, arrangements or affiliations with Actelion, Amgen, Sanofi, Pfizer, Novonordisk, MSD, Recordati, Kowa, Abbott, Novartis, Mylan, Bayer, Servier and Sanovel. L Rydén has received honoraria and research grants from Amgen, Bayer AG, Boehringer Ingelheim, MSD, Novo Nordisk and Sanofi. K. Kotseva received consultancy fees from Amgen. Publisher Copyright: © 2019
(Peer reviewed)